AtriCure to Present at the UBS Global Healthcare Conference

MASON, Ohio--(BUSINESS WIRE)-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it will present at the UBS Global Healthcare Conference at the Grand Hyatt in New York on Monday, May 23, 2016. Management is scheduled to present at 11:00 a.m. Eastern Time. A live audio webcast of the presentation may be accessed by visiting the Investors page of AtriCure’s corporate website at www.atricure.com. A replay of the presentation will be available for 90 days following the presentation.

About AtriCure, Inc.

AtriCure, Inc. is a medical device company providing innovative atrial fibrillation (Afib) solutions designed to produce superior outcomes that reduce the economic and social burden of atrial fibrillation. AtriCure’s Synergy™ Ablation System is the first and only surgical device approved for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures. AtriCure’s AtriClip left atrial appendage management (LAAM) exclusion device is the most widely sold device worldwide that is indicated for the occlusion of the left atrial appendage. The company believes cardiothoracic surgeons are adopting its ablation and LAAM devices for the treatment of Afib and reduction of Afib related complications such as stroke. AtriCure recently acquired nContact, a leader in minimally invasive technology for epicardial ablation. nContact’s mission is to transform the underserved arrhythmia population through a multidisciplinary epicardial-endocardial ablation approach. Afib affects more than 33 million people worldwide. For more information visit AtriCure.com or follow us on Twitter @AtriCure.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160502006040/en/

AtriCure, Inc.
Andy Wade
Senior Vice President and Chief Financial Officer
513-755-4564
[email protected]
or
Investor Relations
Gilmartin Group
Lynn Pieper
415-937-5402
[email protected]

Source: AtriCure, Inc.

You May Also Be Interested In

• Vanta Announces Closing of First Tranche of Private Placement and Board of Directors Update
• Solana Price Prediction Flips Bullish After 70x ETF Surge and Pepeto Draws Thousands of Wallets
• Crypto News Today: AlphaPepe Presale Nears $2.5M Raised as Bitcoin Price Prediction Targets $100,000